Diagnosis of invasive candidiasis in the ICU

Philippe Eggimann¹*, Jacques Bille² and Oscar Marchetti³

Abstract

Invasive candidiasis ranges from 5 to 10 cases per 1,000 ICU admissions and represents 5% to 10% of all ICU-acquired infections, with an overall mortality comparable to that of severe sepsis/septic shock. A large majority of them are due to Candida albicans, but the proportion of strains with decreased sensitivity or resistance to fluconazole is increasingly reported. A high proportion of ICU patients become colonized, but only 5% to 30% of them develop an invasive infection. Progressive colonization and major abdominal surgery are common risk factors, but invasive candidiasis is difficult to predict and early diagnosis remains a major challenge. Indeed, blood cultures are positive in a minority of cases and often late in the course of infection. New nonculture-based laboratory techniques may contribute to early diagnosis and management of invasive candidiasis. Both serologic (mannan, antimannan, and betaglucan) and molecular (Candida-specific PCR in blood and serum) have been applied as serial screening procedures in high-risk patients. However, although reasonably sensitive and specific, these techniques are largely investigational and their clinical usefulness remains to be established. Identification of patients susceptible to benefit from empirical antifungal treatment remains challenging, but it is mandatory to avoid antifungal overuse in critically ill patients. Growing evidence suggests that monitoring the dynamic of Candida colonization in surgical patients and prediction rules based on combined risk factors may be used to identify ICU patients at high risk of invasive candidiasis susceptible to benefit from prophylaxis or preemptive antifungal treatment.

Epidemiology of invasive candidiasis

Whereas in the past, opportunistic mycoses, such as Candida and Aspergillus, typically occurred in immunocompromised hosts, these complications are increasingly observed in nonimmunocompromised surgical and critically ill adult patients [1,2]. These trends were confirmed by a recent large international prevalence survey in ICUs, which reported infections due to Candida and Aspergillus in 17% and 1.4% patients, respectively [3].

Incidence of candidemia

A large epidemiological survey in the United States reported a threefold increase of fungal sepsis during the period 1979-2000, and candidemia was reported to be the third most common cause of nosocomial bloodstream infection (BSI) in critically ill adult patients, representing 11% of all BSI [4,5]. The incidence of candidemia in U.S. hospitals during 2000-2005 increased from 3.65 to 5.56 episodes per 100,000 population [6]. Incidences are usually tenfold higher in the ICUs than in other wards: 3 to 15 episodes per 10,000 ICU patients-days or 2 to 10 cases per 1,000 ICU admissions are reported, with highest rates among surgical patients [1,7].

Data from Europe have shown that the incidence of candidemia may be lower, with proportions ranging from 2-3% of bloodstream isolates [2,8]. A recent national surveillance, including 2,820 cases of fungemia in Denmark during the period 2004-2009, reported an increasing incidence from 7.7 to 8.6 per 100,000 [9]. Despite important regional differences, these data show that Candida is among the top ten bloodstream pathogens and suggest an increasing incidence of candidemia during the past 5 to 10 years.

Distribution of species

A large geographical variation of the proportions of the different Candida species has been reported (Table 1) [2,7-16]. In North and South America, non-albicans Candida species account for more than half of the bloodstream isolates: C. glabrata and C. parapsilosis are the predominant non-albicans species, respectively. Whereas in Europe, C. albicans remains the most...
frequent species, epidemiological trends suggest that non-albicans Candida species, in particular C. glabrata, are emerging. In addition to differences in the fungal ecology of the different continents, the large use of azoles antifungal agents may have contributed to this progressive shift of the epidemiology of candidemia.

**Antifungal susceptibility**

Rates of reduced antifungal susceptibility or resistance ranging from < 5% to > 30% have been reported. The antifungal susceptibility of 2,085 Candida isolates to echinocandins (anidulafungin, micafungin) to new azoles (posaconazole, voriconazole) and to fluconazole were tested in the SENTRY survey according to the new Clinical and Laboratory Standard Institute (CLSI) breakpoints [10]. In C. albicans, no resistance to the five antifungals was observed. In contrast, resistance rates for C. glabrata were reported to be: fluconazole 5.6%, posaconazole 3.7%, voriconazole 3.5%, anidulafungin 2.4%, and micafungin 1.9%, respectively. C. parapsilosis was found to be resistant to fluconazole in 5% of the isolates. C. tropicalis was resistant to fluconazole in 3.2% of isolates, to posaconazole in 0.9%, and to voriconazole in 2.9%. Finally, C. krusei was resistant in 2.5% of cases to voriconazole, whereas no resistance to posaconazole and to the two echinocandins was found. In Denmark, the proportion of fully susceptible species decreased from 79.7% to 68.9% [9]. Leroy et al. reported a decreased susceptibility to fluconazole in 17% of isolates from 180 French ICUs [7].

**Selective pressure of antifungals on species distribution**

Preexposure to antifungals, such as prophylaxis, in particular with azoles, and to a lesser extent with echinocandins, has been associated with the occurrence of breakthrough infections with resistant Candida species. Whereas C. glabrata and C. krusei have been classically observed in these settings, other resistant non-albicans Candida species are being increasingly observed [17,18]. This was recently confirmed in a large prospective multicenter study conducted by the French Mycosis Study Group in 2,441 candidemic patients reporting that preexposure to fluconazole (159 episodes) or caspofungin (61 episodes) was associated with a higher proportion of less drug-susceptible C. glabrata or C. krusei (odds ratio (OR), 2.45; 95% confidence interval (CI), 1.39-4.31) and C. parapsilosis, C. glabrata, or C. krusei (OR, 4.79; 95% CI, 2.47-9.28), respectively [19]. These observations are not only of epidemiological interest, but the decreased in vitro antifungal susceptibility has been showed to be associated with increased morbidity and mortality in both immunocompromised and critically ill patients [7,20].

---

**Table 1 Distribution of Candida species in epidemiological surveys during the past decades**

| Author          | Period of observation | Study      | Region       | No. of strains | Candida albicans | Candida tropicalis | Candida parapsilosis | Candida glabrata | Candida krusei | Other Candida |
|-----------------|-----------------------|------------|--------------|----------------|------------------|--------------------|---------------------|------------------|----------------|--------------|
| Pfaller et al. [10] | 2008-2009             | SENTRY     | Worldwide    | 2085           | 48%              | 11%                | 17%                 | 18%              | 2%             | 4%           |
|                 |                       |            | Europe       | 750            | 55%              | 7%                 | 14%                 | 16%              | 3%             | 4%           |
|                 |                       |            | North America| 936            | 43%              | 11%                | 17%                 | 24%              | 2%             | 4%           |
|                 |                       |            | Latin America| 348            | 44%              | 17%                | 26%                 | 5%               | 1%             | 5%           |
|                 |                       |            | Asia         | 51             | 57%              | 12%                | 14%                 | 14%              | 2%             | 2%           |
|                 |                       |            | Brazil       | 137            | 34%              | 15%                | 24%                 | 10%              | 2%             | 17%          |
| Marra et al. [11] | 2007-2010             | SCOPE      |              |                |                  |                    |                     |                  |                |              |
| Arendrup et al. [9] | 2004-2007             | Denmark    |              | 2901           | 57%              | 5%                 | 4%                  | 21%              | 4%             | 9%           |
| Horn et al. [12]  | 2004-2008             | PATH       | North America| 2019           | 46%              | 8%                 | 16%                 | 26%              | 3%             | 1%           |
| Leroy et al. [7]  | 2005-2006             | AmarCand   | France ICU   | 305            | 57%              | 5%                 | 8%                  | 17%              | 5%             | 8%           |
| Talarmin et al. [13] | 2004                 |            | France West  | 193            | 55%              | 5%                 | 13%                 | 19%              | 4%             | 4%           |
| Bougnoux et al. [14] | 2001-2002             | Paris ICU  |              | 57             | 54%              | 9%                 | 14%                 | 17%              | 4%             | 2%           |
| Marchetti et al. [2]  | 1991-2000             | FUNGINOS   | Switzerland  | 1137           | 64%              | 9%                 | 1%                  | 15%              | 2%             | 9%           |
| Sandven et al. [15] | 1991-2003             |            | Norway Nationwide | 1393        | 70%              | 7%                 | 6%                  | 13%              | 1%             | 3%           |
| Pfaller et al. [16] | 1997-2005             | ARTEMIS    | Mondial **   | 55'229         | 71%              | 5%                 | 5%                  | 10%              | 2%             | 7%           |
| Tortorano et al. [8] | 1997-1999             | ECMM       | Europe       | 2089           | 52%              | 7%                 | 13%                 | 13%              | 2%             | 13%          |
resistance plays an important role for updating treatment recommendations designed to improve patients’ outcome.

Impact of invasive candidiasis
Candidemia typically occurs in colonized patients who accumulate other risk factors, such as major surgery, intravascular catheters, and antibacterial exposure, during a prolonged ICU stay [1,21]. It occurs at a median of 22 days after hospital admission compared with 13 days for *Escherichia coli* and 16 days for *Staphylococcus aureus* bacteremias according to the U.S. population-based SCOPE study [5]. It occurred 14 (interquartile range, IQR, 5-25) days and 19 (± 3) days after ICU admission, in a survey of a university hospital from Paris and in the EPIC II study, respectively [14,22].

Candidemia is associated with significant morbidity, which is reflected by a long ICU and hospital stay, ranging between one and several weeks [7,14]. The overall mortality in patients with invasive *Candida* infections is high: 42.6% in the EPIC II study [22]; 35.2% at 12 weeks in the PATH study [12]; 37.9% in the ECMM study [8]; and 53.4% in non-ICU vs. 85.9% in ICU patients in the Brazilian SCOPE study [11]. In the PATH study, the highest mortality has been reported in *C. krusei* infections (52.9%) and the lowest in *C. parapsilosis* infections (23.7%), whereas intermediate rates were reported for *C. albicans* (35.6%), *C. glabrata* (38.1%), and *C. tropicalis* (41.1%) [12]. Similar differences were found in the ECMM and the French surveys [7,8]. Significant differences in mortality in age groups also were reported: 16.8% in patients 0-19 years of age, 31.3% in 19-65 years of age, and 52.7% in > 65 years of age [12]. Mortality higher than 80% was reported in candidemic patients with septic shock [23]. The mortality attributable to candidemia ranged from 5-49% according to the different types of studies (retrospective vs. prospective), patients (ICU vs. non-ICU, age), and healthcare settings [8,24,25].

A substantial difference in mortality between patients who receive appropriate antifungal therapy (< 5%) and those without appropriate therapy (25-40%) was observed in patients with septic shock [23]. Therapy of candidemia delayed beyond 12 h after sampling of blood has been associated with an increase of in-hospital mortality from < 20% to 40% [26,27]. Because incubation accounts for the majority of the time elapsed between sampling of blood cultures and starting antifungal therapy, these data highlight the need for new noninvasive tools for anticipating diagnosis of invasive candidiasis in high-risk patients, which may play a key role for early and targeted empirical or preemptive treatment strategies [28-30].

Pathogenesis of invasive candidiasis
During past decades, many risk factors associated with the development of invasive candidiasis have been identified (Table 2) [21,31-33]. Among them, *Candida* colonization plays a key role in the pathogenesis of invasive candidiasis. Selective pressure trough antibacterial therapy alters the microbiota, resulting in overgrowth of *Candida* species on skin and mucosal surfaces [1]. Invasive procedures that disrupt natural skin or mucosal barriers, such as intravascular catheters, gastrointestinal tract surgery, and chemotherapy-associated mucositis, as well as decreased host defenses, in particular neutropenia, facilitate local invasion and further candidemia (Figure 1).

Host defenses against colonization of mucous membranes by *Candida* and invasion of tissues and/or dissemination via the bloodstream rely on distinct immunological mechanisms [34]. Recognition of fungi-associated molecular patterns involves several classes of pattern-recognition receptors. Toll-like receptors (TLRs) 2 and 4 recognize fungal cell-wall structures (mannans) and induce the production of proinflammatory cytokines [35]. Beta-1,3 glucans are sensed by dectin-1, a member of the C-type lectin family of receptors. Activation of the signal transduction pathways downstream of these receptors ultimately lead to the production of a complex array of mediators, including proinflammatory cytokines (such as TNF and IL-1) involved in adaptive immune response [36]. CD4+ T cells have been shown to play a critical role in host defenses against Candida infections. The interferon (IFN)-γ-mediated Th1 response stimulates the production of

---

**Table 2 Risk factors associated with the development of invasive candidiasis**

| Risk Factor                                                                 | Definition                                                                 |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Colonization of several body sites                                         | Broad-spectrum antibiotics, Immunosuppression, Burns (> 50%)                |
| Neutropenia                                                                | Disruption of physiological barriers in the digestive tract                |
| Major abdominal surgery                                                    | Surgery of the urinary tract in presence of candiduria                     |
| Major trauma (ISS > 20)                                                    | Major trauma (ISS > 20)                                                    |
| Parenteral nutrition                                                       | Hemodialysis                                                                |
| APACHE II > 20                                                             | Central venous catheter                                                    |
| Candiduria > 10^5 cfu/ml                                                   | Young and old ages                                                         |
| Diabetes                                                                   | Renal failure                                                               |
| Diabetic                                                                   | Recent surgery                                                              |
| Urinary catheter                                                           | Vascular catheters                                                         |
| Prolonged ICU stay (> 7 days)                                              | Multiple transfusions                                                      |
specific anti-
*Candida* immunoglobulins, whose role for prevention and clearance of infection remains to be elucidated [37]. These recent findings open new perspectives for identifying subgroups of patients at higher risk of developing invasive candidiasis and who may benefit from more specifically targeted preventive or preemptive antifungal strategies and/or of immunomodulating approaches [36].

**Diagnosis of candidiasis in critically ill patients**

Only 5-15% of patients are colonized by *Candida* spp. at ICU admission, but this proportion progressively increases with time to 50-80% as a result of prolonged exposure to many risk factors, such as major surgery, parenteral nutrition, dialysis, and antibiotics [33,38-40]. However, only 5-30% of colonized patients will develop invasive candidiasis, which is usually a late-onset ICU acquired infection [7,14]. As the clinical differentiation between colonized and infected critically ill patients remains difficult to assess, the utility and cost-effectiveness of colonization surveillance cultures remain unclear [41-43].

Two main types of *Candida* infections predominate. Candidemia occurs generally after several days or weeks of ICU stay, whereas *Candida* peritonitis more closely follows a complicated abdominal surgery. Conventional blood cultures, as well as cultures of other sterile body sites, albeit late and insensitive, remain the key diagnostic tools to identify *Candida* to the species level, and allow to test the activity of various antifungal agents.

Cultures from sites other than blood or normally sterile body fluids are nonspecific and reflect colonization in the majority of cases. Blood cultures become positive in a minority of patients with deep-seated candidiasis and often only late in the course of infection [7,14,22]. Conventional identification of *Candida* to the species level usually requires 1 to 3 days after detection of fungal growth in blood cultures. The recent development of new laboratory techniques (fluorescent in situ hybridization [FISH], and matrix-assisted laser desorption ionization time of flight mass-spectrometry [MALDITOF-MS]), significantly help to reduce the delay to species level identification, and thus allow an earlier choice of appropriate antifungal therapy [44].

Invasive candidiasis other than candidemia is difficult to diagnose. Clinical signs suggestive of invasive candidiasis did not differ from those of other nosocomial infections. More specific manifestations, such as retinal emboli (cotton wool) or hepatosplenic lesions are rare or only observed in cancer patients after neutrophils recovery [45,46]. Tissue sampling often requires invasive procedures at high risk of complications and has a low diagnostic yield, especially in patients who have received empirical therapy.

**Nonculture-based methods**

The delay between ICU admission and the occurrence of deep-seated *Candida* infections allows both to identify patients at increased risk and to attempt to detect early onset of infections. Several biomarkers are...
currently tested with this strategy, either based on antigen-antibody detection or on fungal DNA detection in serum or blood.

Commercially available antigen-based test target a *Candida* specific cell-wall component, mannan, or a non-specific fungal element, beta-D-glucan. Both have a moderate sensitivity (60% for mannan, 83% when combined to anti-mannan antibodies, 65-80% for beta-D-glucan) and are intended to be used as a screening strategy two to three times per week. Mostly tested in oncology patients, their value in an ICU population is still insufficiently documented [47,48].

The second noncultural approach relies in detecting the presence of *Candida* DNA in the blood of at-risk patients. The major hurdle to this technique is the lack of commercial easy-to-use methods and the relative low sensitivity of this approach, due to several factors (low quantity of *Candida* cells in the blood, inhibitors due to blood cells). An additional difficulty is the “gold standard” generally used in evaluations, blood cultures, which itself lacks sensitivity. Available comparative studies in ICU patients are limited, showing a sensitivity equal to/or slightly lower than blood cultures (75-100% compared with blood cultures) [49,50].

**Clinical prediction of invasive candidiasis in critically ill patients**

Despite continuous progress and developments in this field, the absence of laboratory-based method currently available at the bedside has imposed pragmatic clinical approaches based on the appreciation of the dynamics of colonization and/or of the combination of less specific risk factors [51].

**Colonization-based assessment of the risk of invasive candidiasis**

Documentation of increasing amounts of *Candida* spp. in semiquantitative cultures from multiple sites has been found to predict the subsequent development of invasive candidiasis [21,52,53]. It has been suggested that the presence of *Candida* spp. in more than two body sites may justify the start of antifungal therapy [54,55]. However, critically ill patients are being colonized progressively during their ICU stay. The accuracy of a single-point assessment is low and such rule may be responsible for overuse of antifungals [56]. As initially proposed by Pittet et al. and confirmed by other investigators, a periodic evaluation of the dynamics of colonization in surgical patients at risk may predict more accurately the development of an invasive candidiasis [21,57-60].

In a prospective cohort study of surgical critically-ill patients, Pittet et al. assessed the degree of colonization by measuring daily the colonization index defined as the ratio of the number of distinct body sites colonized with genotypically identical strains of *Candida* over the total number of sites tested [21]. Eleven of 29 heavily colonized patients developed invasive candidiasis. The severity of the underlying conditions and the degree of colonization independently predicted the occurrence of invasive candidiasis. The average *Candida* colonization index was 0.47 for colonized vs. 0.7 for infected patients, respectively (\( p < 0.01 \)). Furthermore, a threshold ≥0.5 identified all infected patients at an average of 6 days before the diagnosis of invasive candidiasis.

The usefulness of the colonization index has never been demonstrated in a large prospective clinical trial, but its potential clinical value has been suggested in at least nine studies. Dubau et al. reported that an invasive candidiasis developed in only 1 of 35 surgical patients in whom empirical antifungals were prescribed when the index reached 0.5 and that it decreased rapidly in the 34 other patients [61]. Garbino et al. prospectively observed a decrease of the index in a group of critically ill patients receiving antifungal prophylaxis [42]. In contrast, it increased with time in those who received a placebo. Differences reached statistical significance between the two groups after 7 days. Chabasse et al. found a correlation between quantitative urine cultures above 10⁵ cfu/mL and a colonization index ≥0.5 [62]. Charles et al. reported significantly higher values in medical patients (0.74 ± 0.31) compared with surgical patients 0.45 ± 0.4 (\( p = 0.01 \)) [57]. The index increased significantly by 0.1 during the ICU stay (\( p = 0.016 \)) and the threshold of 0.5 was reached in 36 (39.1%) of 92 nonsurgical ICU patients staying > 7 days; 6 of them developed invasive candidiasis [63]. Hematological malignancy, duration of exposure to broad-spectrum antibiotics, fungal colonization at entry, and candiduria predicted an increase in the colonization index. In contrast, the duration of exposure to antifungals was significantly associated with its decrease. Compared with an historical cohort of 455 controls, the rate of invasive candidiasis decreased from 7% to 3.6% in a cohort of 478 surgical ICU patients who received preemptive antifungal treatment if the corrected colonization index was > 0.4 [64]. This strategy avoided the development of ICU-acquired invasive candidiasis. Normand et al. reported a significant reduction of the colonization index in a cohort of 98 patients mechanically ventilated > 48 hours randomized to receive prophylaxis by oral nystatin [65]. Agvald-Öhman et al. showed that increases of colonization index after major abdominal surgery were significantly correlated with the development of an IAB [59]. Senn et al. reported a significant decrease of the colonization index in critically ill patients empirically treated with caspofungin after recurrent gastrointestinal perforation/anastomotic leakage or acute necrotizing pancreatitis [60].

Although these observations strongly suggests that the colonization index may be used to identify among
colonized critically ill patients those who are susceptible to benefit from early initiation of antifungal therapy, this strategy is work-intensive, expensive, and difficult to implement on a routine basis at the bedside [66]. Its cost-effectiveness and usefulness for the management of critically ill patients remains to be proved in prospective comparative clinical trials [30]. In addition, limited data are available for nonsurgical patients.

**Risk of invasive candidiasis assessed by scores or predictive rules**

Scoring systems or predictive rules that combine clinical risk factors and information for *Candida* colonization have been recently proposed [67-69]. A risk-based “Candida score” has been developed by Leon et al. in a prospective cohort of 1,699 ICU patients staying more than 7 days [68]. Surgery (OR, 2.71; 95% CI, 1.45-5.06), multifocal colonization (OR, 3.04; 95% CI, 1.46-6.39), total parenteral nutrition (OR, 2.48; 95% CI, 1.16-5.31), and severe sepsis (OR, 7.68; 95% CI, 4.14-14.22) significantly predicted invasive candidiasis. By attributing one point of each risk factor, the score for a cutoff value of 2.5 had a sensitivity and specificity of 81% and 74%, respectively. The usefulness of this risk-factor based “Candida score” has been demonstrated further to rule out invasive candidiasis [70]. In a multicenter cohort of 1,007 patients staying for more than 7 days, only 13 of 565 (2.3%) patients with a score < 3 points developed a candidiasis, corresponding to a negative predictive value of 98%. In this series, a linear progression of the risk of invasive candidiasis and higher score was further observed. The accuracy of a colonization index ≥0.5 (relative risk, 5.98, 95% CI, 3.28-10.92) was lower than a Candida score ≥3 (relative risk, 5.98; 95% CI, 3.28-10.92).

Using a similar conceptual approach, Paphitou et al. identified retrospectively individual risk factors for the

---

**Table 3 Criteria used for antifungal prophylaxis in adult critically ill patients**

| Study | Criteria used for prophylaxis | Antifungal used for prophylaxis | Invasive candidiasis | Commentary |
|-------|--------------------------------|---------------------------------|----------------------|------------|
| **Positive prophylactic studies** | | | | |
| *Slotman et al. 1987 [77]* | Abdominal surgery + ≥ 3 risk factors | Ketoconazole 200 mg/d PO Placebo | 0/27 (0%) 5/30 (17%)‡ | Costs: $4,800 vs. $10,000‡ LOS: 6.0 vs. 12.5 days‡ |
| *Savino et al. 1992 [78]* | Surgical patients + hypermetabolism | Nystatin/orfloxac PO Placebo | 6/25 (24%) 13/21 (62%)§ | Nil per patient: 0.9 vs. 2.1§ |
| Desai et al. 1992 [79]* | Severely burned patients | Nystatin/polymyxin SDD No prophylaxis | 34/1042 (3.3%) 0/1459 (0%)† | Superficial infections: 59 (21%) vs. 22 (10%)‡ |
| Eggimann et al. 1999 [39]* | Abdominal surgery + tertiary peritonitis | Fluconazole 400 mg/d IV Placebo | 1/23 (9%) 7/20 (35%)§ | Candida peritonitis 1 (4%) vs. 7 (35%)§ |
| Pelz et al. 2001 [43]* | Surgical patients 3 risk factors | Fluconazole 400 mg/d PO Placebo | 11/130 (8%) 20/130 (15%)§ | > 75% colonized at randomization |
| Garbino et al. 2002 [42]* | Mechanically ventilated > 96 h | Fluconazole 100 mg PO + SDD Placebo + SDD | 4/101 (4%) 10/101 (10%)§ | Candidemia: 9 vs. 1 (RR 0.1; CI 0.02-0.74)¶ |
| Jacobs et al. 2003 [80]* | ICU + septic shock | Fluconazole 200 mg IV/d Placebo | 0/32 (0%) 1/39 (3%)§ | Mortality significantly reduced in peritonitis |
| He et al. 2003 [81]* | Severe acute pancreatitis | Fluconazole 100 mg IV/d Placebo | 2/22 (9%)§ 7/23 (30%)§ | Mortality 2/2 (100%) Mortality 3/7 (43%) |
| **Negative prophylactic studies** | | | | |
| Savino et al. 1994 [78] | Surgical patients + LOS > 2 days | Nystatin 2 × 10⁶ 4 ×/d PO Placebo | 5/57 (7%) 1/65 (2%)§ | Mortality rates NS 4/53 (8%) vs. 8/56 (14%) |
| Ablens et al. 2000 [82]* | Surgical patients + LOS > 2 days + other risk factors | Ketoconazole 200 mg/d PO Clotrimazole 10 mg 3 ×/d PO Placebo | 1/65 (2%) 1/80 (1%)§ 2/72 (3%)§ | |
| Sandven et al. 2002 [40]* | Surgery for peritonitis | Fluconazole 3 mg/kg 3 ×/w Placebo | 8/60 (13%) 11/59 (19%)§ | |
| Schuster et al. 2008 [83]* | ICU ≥ 4 d + Fever > 4 d under broad-spectrum antibiotics + APACHE II ≥ 16 | Fluconazole 400 mg/d IV Placebo | 6/122 (5%) 11/127 (9%)§ | |

*Prospective randomized double-blind

↑ p < 0.05

↓ Not significant
development of invasive candidiasis in a cohort of 327 surgical ICU patients to build a predictive rule [71]. The rate of invasive candidiasis was 17% for patients staying more than 3 days in ICU, with the combination of diabetes mellitus, dialysis, total parenteral nutrition, and exposure to broad-spectrum antibiotics compared with 5% for those lacking these characteristics ($p < 0.01$). Fifty-two percent of patients met this rule, which captured 78% of those who developed invasive candidiasis. For patients staying 4 days or more, Ostrosky-Zeichner et al. refined this preliminary clinical prediction rule in a large multicenter retrospective study [72]. Any systemic antibiotics or the presence of a central venous catheter during the 3 preceding days and at least two of the preceding risk factors was able to identify patients with a risk of invasive candidiasis of at least 10%. However, with a sensitivity of 34% this rule captured only one third of cases of invasive candidiasis. The usefulness of a risk-factors-based predictive rule has been suggested in a medical ICU where antifungals were empirically prescribed accordingly [73]. Thirty-six (2.6%) of all patients admitted received antifungals empirically, allowing a significant decrease of the rate of fungal catheter-related bloodstream infections from 3.4 to 0.79 episodes per 1,000 catheter-days. The sensitivity of such clinical predictive rule was markedly improved (66%) with a maintained specificity (87%) by taking into account the presence of Candida colonization at time of its assessment [74]. This new rule is currently investigated in a randomized, placebo-controlled, pilot study on empirical therapy with caspofungin in high-risk ICU patients (MSG-04 in mixed patients, INTENSE study in surgical patients, http://www.clinicaltrials.gov).

However, the common characteristics of risk scores and clinical rules is not their relatively low positive predictive value for diagnosing invasive candidiasis but their high negative predictive value for ruling out infection. This may allow withholding a number of unnecessary antifungal treatments in critically ill patients.

Management of invasive candidiasis in critically ill patients

Rapid initiation of appropriate antifungal therapy has been shown to reduce mortality in patients with candidemia [24,75]. Prophylaxis should strongly be restricted to very specific subgroups of patients in whom it has been demonstrated to be useful (Table 3). Preemptive therapy for colonized patients or those with high-risk scores and empirical therapy in septic patients not responding to appropriate antibacterial treatment are possible early interventions (Figure 2) [28,60].

Practical approach to early diagnosis of invasive candidiasis in critically ill patients

Although recognized as a strong risk factor, colonization, which may occur early after ICU admission, does not justify the start of empirical antifungal treatment [76]. Despite promising preliminary results, biomarkers are currently only available for research purpose. Accordingly, clinicians should continue to combine risk factors and the dynamic of colonization to try to identify...
early critically ill patients susceptible to benefit from early empirical antifungal treatment (Figure 3).

**Author details**

1. Adult Critical Care Medicine and Burn Centre, Centre Hospitalier Universitaire Vaudois (CHUV) – BH 08-619, Bugnon 46 CH-1011 Lausanne, Switzerland
2. Institute of Microbiology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
3. Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois (CHUV), and University of Lausanne (UNIL), Lausanne, Switzerland

**Authors’ contributions**

PE, JB and OM designed the structure of this review, wrote dedicated original sections and contributed to finalize MS.

**Competing interests**

Pertinent to this article, PE received research grants and/or educational grants and/or speaker's honoraria from the (in alphabetic order): Astellas, Merck, Sharp & Dohme-Chibret, and Pfizer. JB has no disclosures regarding this manuscript. OM received unrestricted research grants and/or educational grants and/or speaker’s honoraria and/or consultant’s honoraria from (in alphabetical order): Foundation for the Advancement in Medical Microbiology and Infectious Diseases FAMMID, Associates of Cape Code, BioMérieux-Cepheid, Bio-Rad, Essex Schering-Plough, Gilead, Merck, Sharp & Dohme-Chibret, Novartis, Pfizer, Roche Diagnostics, Wako.

Received: 6 July 2011 Accepted: 1 September 2011

**References**

1. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patient. *Lancet Infect Dis* 2003, 3:685-702.

2. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Calandra T, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends 1991-2000. *Clin Infect Dis* 2004, 38:312-319.

3. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. *JAMA* 2009, 302:2932-2939.

4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003, 348:1546-1554.

5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide study. *Clin Infect Dis* 2004, 39:309-317.

6. Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. *Infect Control Hosp Epidemiol* 2008, 29:978-980.

7. Leray O, Gangneux JP, Montrasves P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). *Crit Care Med* 2009, 37:1612-1618.

8. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Kingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. *Int J Antimicrob Agents* 2006, 27:359-366.

9. Arendrup MC, Bruun B, Christensen JJ, Fournier K, Johansen HK, Kjaergaard P, et al. National surveillance of fungemia in Denmark (2004 to 2009). *J Clin Microbiol* 2011, 49:325-334.

10. Pfaffer MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). *J Clin Microbiol* 2011, 49:396-399.

11. Mara AR, Camargo LF, Pignatari AC, Sukennik T, Behar PR, Meideiros EA, et al. Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. *J Clin Microbiol* 2011, 49:1866-1871.
12. Horn DL, Neofytos D, Anaisse EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. *Clin Infect Dis* 2009, 48:1695-1703.

13. Talarmin JP, Bouteille D, Tattevin P, Dargere S, Weinbreck P, Ansart S, et al. [Epidemiology of candidemia: a one-year prospective observational study in the west of France]. *Med Mal Infect* 2009, 39:87-88.

14. Bougnoux ME, Kac G, Aegerter P, d'Enfert C, Fagon JY. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. *Intensive Care Med* 2008, 34:292-299.

15. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. *J Clin Microbiol* 2006, 44:1977-1981.

16. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Delaying the empiric treatment of Candida bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. *The National Epidemiology of Mycosis Survey. Clin Infect Dis* 2001, 33:177-186.

17. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Recent exposure to caspofungin or fluconazole influences the yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. *J Clin Microbiol* 2007, 45:1735-1745.

18. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, et al. Candidemia in cancer patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. *Cancer* 2009, 115:4745-4752.

19. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. *Crit Care Med* 1999, 27:1066-1072.

20. Sandven P, Qvist H, Skulvand E, Giercksky KE. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. *Crit Care Med* 2002, 30:541-547.

21. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. *Lancet* 1989, 1:1437-1440.

22. Bougnoux ME, Kac G, Aegerter P, d’Enfert C, Fagon JY. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. *Intensive Care Med* 2008, 34:292-299.

23. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. *Cancer* 2009, 115:4745-4752.

24. Viscoli C, Girmania C, Marinus A, Collette L, Martino P, Vandercam B, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). *Clin Infect Dis* 1999, 28:1071-1079.

25. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Factors influencing the attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. *Clin Infect Dis* 2005, 41:1232-1239.

26. Morrell M, Fraser V, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. *Antimicrob Agents Chemother* 2005, 59:3540-3545.

27. Gudlaugsson O, Gillespie S, Lee K, Vande BJ, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. *Clin Infect Dis* 2003, 37:172-177.

28. Carey KW, Rege MA, Pao MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. *Clin Infect Dis* 2006, 43:25-31.

29. Playford EG, Eggimann P, Calandra T. Antifungals in the ICU. *Curr Opin Crit Care* 2008, 24:610-619.

30. Pappas PG, Kaufman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009, 49:535-555.

31. Eggimann P, Ostrosky-Zeichner L. Early antifungal intervention strategies in ICU patients. *Curr Opin Crit Care* 2010, 16:465-469.

32. Wey SB, Moni M, Pfaffer MA, Woodson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. *Arch Intern Med* 1985, 149:2349-2353.

33. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaffer MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. *J Clin Microbiol* 1994, 32:975-980.
Antifungal Therapy (TREAT Study). Abstracts of the 48th ICAAC, 20-22 October 2008, Chicago, IL.

55. Inhibiting candida infection in the intensive care unit: observations from a randomized clinical trial. J Crit Care 2007, 22:237-244.

56. Eggimann P, Calandra T, Fluckiger U, Bille J, Garbino J, Gläuser M, et al. Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. Intensive Care Med 2005, 31:1514-1521.

57. Sloman GJ, Burchard KW. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987, 122:147-151.

58. Savino JA, Agarwal N, Why P, Polkastro A, Cerabona T, Austria L. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994, 36:20-25.

59. Desai MH, Rutan RL, Heggars JP, Herndon DN. Candida infection with and without nystatin prophylaxis. A 11-year experience with patients with burn injury. Arch Surg 1992, 127:159-162.

60. Jacobs S, Price ED, Tariq M, Al Omar NF. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med 2003, 31:1938-1946.

61. He YM, Lv YS, Ai ZL. Prevention and therapy of fungal infection in severe acute pancreatitis: a prospective clinical study. World J Gastroenterol 2003, 9:2619-2622.

62. Ablès AZ, Blumer NA, Valanis GT, Godenick MT, Kajdasz DK, Paleish YY. Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000, 9:169-175.

63. Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Scheld WM, et al. Prevention and therapy of fungal infection in severe burn injury. Without nystatin prophylaxis. A 11-year experience with patients with burn injury. Arch Surg 1992, 127:159-162.

64. Commission on Accreditation of Rehabilitation Facilities. The joint commission on accreditation of rehabilitation facilities. 2001.

65. Eggimann P, Calandra T, Fluckiger U, Bille J, Garbino J, Gläuser M, et al. Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. Intensive Care Med 2005, 31:1514-1521.

66. Sloman GJ, Burchard KW. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987, 122:147-151.

67. Savino JA, Agarwal N, Why P, Polkastro A, Cerabona T, Austria L. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994, 36:20-25.

68. Desai MH, Rutan RL, Heggars JP, Herndon DN. Candida infection with and without nystatin prophylaxis. A 11-year experience with patients with burn injury. Arch Surg 1992, 127:159-162.

69. Jacobs S, Price ED, Tariq M, Al Omar NF. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med 2003, 31:1938-1946.

70. He YM, Lv YS, Ai ZL. Prevention and therapy of fungal infection in severe acute pancreatitis: a prospective clinical study. World J Gastroenterol 2003, 9:2619-2622.

71. Ablès AZ, Blumer NA, Valanis GT, Godenick MT, Kajdasz DK, Paleish YY. Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000, 9:169-175.

72. Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer KW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008, 149:83-90.

73. Faiz S, Neale B, Rios E, Campoes T, Parsley E, Patel B, et al. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis 2009, 28:689-692.

74. Ostrosky-Zeichner L, Aranah L, Eggimann P, Garbino J, Herbrecht R, Leon C, et al. Preliminary results of a multicenter, international, retrospective, study to validate a clinical prediction rule (CPR) to identify critically-ill patients at risk of invasive candidiasis (IC) for TReatment with Empirical